These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28369698)

  • 1. In vitro gene expression-coupled bacterial cell chip for screening species-specific antimicrobial enzymes.
    Kwon SJ; Kim D; Lee I; Kim J; Dordick JS
    Biotechnol Bioeng; 2017 Aug; 114(8):1648-1657. PubMed ID: 28369698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel recombinant endolysin ointment with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from wounds and burns.
    Hamed ZO; Awni AA; Abdulamir AS
    Arch Microbiol; 2023 Mar; 205(4):104. PubMed ID: 36869962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel
    Cater K; Dandu VS; Bari SM; Lackey K; Everett GF; Hatoum-Aslan A
    mSphere; 2017; 2(2):. PubMed ID: 28357414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-Function Relationships in Phage-Encoded Bacterial Cell Wall Lytic Enzymes and Their Implications for Phage-Derived Product Design.
    Vázquez R; García E; García P
    J Virol; 2021 Jun; 95(14):e0032121. PubMed ID: 33883227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and Genomic Analysis of a Novel Jumbo Bacteriophage vB_StaM_SA1 Infecting
    Zhang B; Sun H; Zhao F; Wang Q; Pan Q; Tong Y; Ren H
    Front Microbiol; 2022; 13():856473. PubMed ID: 35572667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the direct antimicrobial activity of Lysep3 against Escherichia coli by inserting cationic peptides into its C terminus.
    Ma Q; Guo Z; Gao C; Zhu R; Wang S; Yu L; Qin W; Xia X; Gu J; Yan G; Lei L
    Antonie Van Leeuwenhoek; 2017 Mar; 110(3):347-355. PubMed ID: 27943012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered Lysins With Customized Lytic Activities Against Enterococci and Staphylococci.
    Binte Muhammad Jai HS; Dam LC; Tay LS; Koh JJW; Loo HL; Kline KA; Goh BC
    Front Microbiol; 2020; 11():574739. PubMed ID: 33324362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives.
    Borysowski J; Lobocka M; Międzybrodzki R; Weber-Dabrowska B; Górski A
    BioDrugs; 2011 Dec; 25(6):347-55. PubMed ID: 22050337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacteriophage lytic enzymes: novel anti-infectives.
    Fischetti VA
    Trends Microbiol; 2005 Oct; 13(10):491-6. PubMed ID: 16125935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective.
    Fischetti VA
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29875339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection.
    Schmelcher M; Shen Y; Nelson DC; Eugster MR; Eichenseher F; Hanke DC; Loessner MJ; Dong S; Pritchard DG; Lee JC; Becker SC; Foster-Frey J; Donovan DM
    J Antimicrob Chemother; 2015 May; 70(5):1453-65. PubMed ID: 25630640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Phage Lysin LysA2 for Use in Improved Purity Assays for Live Biotherapeutic Products.
    Dreher-Lesnick SM; Schreier JE; Stibitz S
    Viruses; 2015 Dec; 7(12):6675-88. PubMed ID: 26694451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacteriophage lysins as effective antibacterials.
    Fischetti VA
    Curr Opin Microbiol; 2008 Oct; 11(5):393-400. PubMed ID: 18824123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysin Therapy for Staphylococcus aureus and Other Bacterial Pathogens.
    Fischetti VA
    Curr Top Microbiol Immunol; 2017; 409():529-540. PubMed ID: 26728063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteriophage endolysins against gram-positive bacteria, an overview on the clinical development and recent advances on the delivery and formulation strategies.
    Ho MKY; Zhang P; Chen X; Xia J; Leung SSY
    Crit Rev Microbiol; 2022 May; 48(3):303-326. PubMed ID: 34478359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gram-Negative Bacterial Lysins.
    Ghose C; Euler CW
    Antibiotics (Basel); 2020 Feb; 9(2):. PubMed ID: 32054067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered bacteriophage lysins as novel anti-infectives.
    Yang H; Yu J; Wei H
    Front Microbiol; 2014; 5():542. PubMed ID: 25360133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriophage-derived endolysins to target gram-negative bacteria.
    Lai WCB; Chen X; Ho MKY; Xia J; Leung SSY
    Int J Pharm; 2020 Nov; 589():119833. PubMed ID: 32877733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Antibacterial Activity Assessment of Chimeric Lysins.
    Park JM; Kim JH; Kim G; Sim HJ; Ahn SM; Choi KS; Kwon HJ
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel method to control pathogenic bacteria on human mucous membranes.
    Fischetti VA
    Ann N Y Acad Sci; 2003 Apr; 987():207-14. PubMed ID: 12727641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.